GLP-1 Pipeline Tracker (2026)
Every late-stage investigational anti-obesity drug — retatrutide, MariTide, CagriSema, survodutide, pemvidutide, petrelintide, mazdutide, ecnoglutide, and bimagrumab+semaglutide — tracked by NCT ID, primary completion date, sponsor, and verified topline results.
About this tracker
This page tracks every investigational anti-obesity drug in late-stage clinical development as of May 2026. The four most-watched programs are retatrutide (Eli Lilly triple agonist, TRIUMPH phase 3), MariTide (Amgen monthly GIPR/GLP-1 conjugate, MARITIME phase 3), CagriSema (Novo Nordisk cagrilintide+semaglutide, REDEFINE phase 3), and survodutide (Boehringer Ingelheim / Zealand, SYNCHRONIZE phase 3). Every NCT ID below was verified directly on ClinicalTrials.gov. Every PMID was confirmed by direct PubMed lookup. Trial readout dates and FDA approval timelines change frequently — verify against the current ClinicalTrials.gov record before making any clinical or investment decision.
YMYL notice: Investigational drugs are not FDA-approved for general use. This tracker is for informational purposes only. None of the drugs below are commercially available outside of clinical trials (except Foundayo, which is FDA-approved for chronic weight management). Compounded retatrutide is not eligible under FDA 503A or 503B; this article does not endorse any compounded product. See our retatrutide regulatory framework article for access timeline context. Trial-to-trial weight-loss percentages are not directly comparable across drugs because trial duration, comparator, dose, and population differ.
Recent readouts
Full pipeline tracker table
All NCT IDs verified on ClinicalTrials.gov. All PMIDs confirmed by direct PubMed lookup. Trial-to-trial weight-loss percentages are not directly comparable — trial duration, comparator, dose, and population differ across every entry below.
| Drug | Sponsor | Mechanism | Indication | Phase | Trial / NCT | Primary Completion | Status |
|---|---|---|---|---|---|---|---|
| RetatrutideLY3437943 | Eli Lilly | GIP / GLP-1 / glucagon triple agonist | Obesity (without T2D) | Phase 3 | TRIUMPH-1 NCT05929066 | April 2026 | Active, not recruiting |
| RetatrutideLY3437943 | Eli Lilly | GIP / GLP-1 / glucagon triple agonist | T2D + obesity | Phase 3 | TRIUMPH-2 NCT05929079 | May 2026 | Active, not recruiting |
| RetatrutideLY3437943 | Eli Lilly | GIP / GLP-1 / glucagon triple agonist | BMI ≥27 + ASCVD or CKD (CVOT/renal) | Phase 3 | TRIUMPH-3 / Outcomes NCT06383390 | February 2029 | Active, not recruiting |
| RetatrutideLY3437943 | Eli Lilly | GIP / GLP-1 / glucagon triple agonist | Obesity + knee osteoarthritis | Phase 3 | TRIUMPH-4 NCT05931367 | November 14, 2025 | Completed |
| Maridebart cafraglutideMariTide | Amgen | GIPR antagonist + GLP-1 agonist mAb-peptide (monthly Q4W) | Obesity (without T2D) | Phase 3 | MARITIME-1 NCT06858839 | January 2027 | Active, not recruiting |
| Maridebart cafraglutideMariTide | Amgen | GIPR antagonist + GLP-1 agonist mAb-peptide (monthly Q4W) | T2D + obesity | Phase 3 | MARITIME-2 NCT06858878 | January 2027 | Active, not recruiting |
| CagriSemacagrilintide 2.4 mg + semaglutide 2.4 mg | Novo Nordisk | Amylin analog + GLP-1 agonist fixed-dose combo | Obesity (without T2D) | Phase 3 | REDEFINE-1 NCT05567796 | October 2024 | Active, not recruiting |
| CagriSemacagrilintide 2.4 mg + semaglutide 2.4 mg | Novo Nordisk | Amylin analog + GLP-1 agonist fixed-dose combo | T2D + obesity | Phase 3 | REDEFINE-2 NCT05394519 | January 2025 | Completed |
| CagriSemacagrilintide 2.4 mg + semaglutide 2.4 mg | Novo Nordisk | Amylin analog + GLP-1 agonist fixed-dose combo | Established CVD (event-driven CVOT) | Phase 3 | REDEFINE-3 NCT05669755 | September 2027 | Active, not recruiting |
| SurvodutideBI 456906 | Boehringer Ingelheim / Zealand Pharma | GLP-1 / glucagon dual agonist | Obesity (without T2D) | Phase 3 | SYNCHRONIZE-1 NCT06066515 | December 2025 | Completed |
| Orforglipron / FoundayoOral non-peptide GLP-1 RA (FDA-approved) | Eli Lilly | Non-peptide oral GLP-1 receptor agonist | OSA + obesity (expansion) | Phase 3 expansion | ATTAIN-OSA NCT06649045 | November 2026 | Approved (expansion) |
| EcnoglutideXW003 | Sciwind Biosciences | Weekly GLP-1 receptor agonist | Chronic weight management (China; no US filing) | Phase 3 | SLIMMER NCT05813795 | June 2024 | Completed |
| PemvidutideALT-801 | Altimmune | GLP-1 / glucagon dual agonist | Obesity / MASH (FDA Fast Track for MASH) | Phase 2 / 2b | MOMENTUM / IMPACT NCT05989711 | April 2025 | Completed |
| Bimagrumab + SemaglutideBYM338 + semaglutide (via Versanis) | Eli Lilly (Versanis acquisition) | Activin type II receptor blocker + GLP-1 agonist | Obesity — fat mass reduction | Phase 2 | BELIEVE NCT05616013 | May 2024 | Completed |
| MazdutideIBI362 | Innovent / Eli Lilly (China license) | GCG / GLP-1 dual agonist | Chronic weight management (China; no US filing) | Phase 3 | GLORY-2 NCT06164873 | June 2025 | Active, not recruiting |
| PetrelintideZP8396 | Zealand Pharma / Roche | Long-acting amylin analog | Obesity (dose-finding; Phase 3 planned H2 2026) | Phase 2 | ZUPREME-1 NCT06662539 | September 2025 | Completed |
Last verified: May 9, 2026. Pipeline status changes frequently. Always confirm against the current ClinicalTrials.gov record.
Per-drug profiles
Retatrutide (LY3437943) — Eli Lilly
Retatrutide simultaneously activates GIP, GLP-1, and glucagon receptors. The glucagon component is hypothesized to increase energy expenditure beyond what dual-agonism achieves. The phase 2 trial (Jastreboff et al., NEJM 2023, PMID 37366315) produced approximately 24.2% mean weight loss at 48 weeks at the highest dose.
YMYL: Retatrutide has not been submitted to the FDA for approval as of May 2026. We cannot predict approval timing. Compounded retatrutide is not eligible under FDA 503A or 503B. See our retatrutide regulatory framework article for full context.
Maridebart Cafraglutide (MariTide) — Amgen
MariTide is a monoclonal antibody-peptide conjugate enabling once-monthly (Q4W) subcutaneous dosing. Phase 2 published in NEJM 2025 (Jastreboff et al., PMID 40549887, NEJM 2025;393:843–857): −12.3% to −16.2% vs −2.5% placebo at Week 52. NOTE: some secondary sources cite “Nature Medicine Dec 2024” for MariTide — that is incorrect. The peer-reviewed publication is NEJM 2025.
Amgen press release (Nov 26, 2024) verbatim: “MariTide demonstrated up to ~20% average weight loss at week 52 without a weight loss plateau.”
CagriSema — Novo Nordisk
CagriSema combines semaglutide 2.4 mg (GLP-1 agonist) with cagrilintide 2.4 mg (long-acting amylin analog). Cagrilintide monotherapy Phase 2 was published as Lau et al., Lancet 2021 (PMID 34798060).
Survodutide (BI 456906) — Boehringer Ingelheim / Zealand Pharma
Phase 2 published as le Roux et al., Lancet Diabetes & Endocrinology 2024 (PMID 38330987). Note: some secondary sources cite NEJM 2024 for survodutide — that is incorrect. The published Phase 2 is Lancet Diabetes & Endocrinology 2024.
SYNCHRONIZE-1 (NCT06066515) — obesity without T2D — completed December 2025. Boehringer topline: up to 16.6% mean weight loss vs 3.2% placebo at Week 76. Peer-reviewed publication is pending; this figure is sourced from manufacturer release only.
Petrelintide (ZP8396) — Zealand Pharma / Roche
ZUPREME-1 (NCT06662539) completed September 2025. Zealand topline (March 2026): up to 10.7% mean body weight reduction at Week 42 vs 1.7% placebo. Zealand and Roche announced in April 2026 intent to advance to Phase 3 with planned initiation in H2 2026. ZUPREME-2 (NCT06926842, T2D + obesity) is also enrolling.
Pemvidutide (ALT-801) — Altimmune
MOMENTUM Phase 2 obesity topline (ADA 2024): −10.3% / −11.2% / −15.6% at 1.2/1.8/2.4 mg vs −2.2% placebo at Week 48. Press release / topline only; peer-reviewed PMID not yet verified. IMPACT Phase 2b MASH (NCT05989711) completed April 2025. Altimmune holds FDA Fast Track designation for MASH.
Bimagrumab + Semaglutide (BELIEVE) — Eli Lilly (Versanis)
BELIEVE (NCT05616013) completed May 2024. Reported topline: combo arm −22.1% total weight loss; 92.8% of weight loss from fat mass.
Hedge: Lilly has not committed to a Phase 3 for bimagrumab. The combination's path forward is uncertain based on Lilly public statements in 2025–2026.
Mazdutide (IBI362) — Innovent / Eli Lilly (China License)
GLORY-2 (NCT06164873) had primary completion June 2025. NMPA-approved in China for chronic weight management (Jun 2025) and glycemic control (Sep 2025).
YMYL: No FDA NDA filed in the United States. Approval in China does not predict FDA approval. No peer-reviewed PMID for GLORY-2 was confirmed at time of publication.
Ecnoglutide (XW003) — Sciwind Biosciences
SLIMMER Phase 3 (NCT05813795) completed June 2024. NMPA-approved in China for chronic weight management March 2026.
YMYL: No FDA NDA filed. Approval in China does not predict FDA approval in the United States.
Orforglipron / Foundayo — Eli Lilly (FDA-Approved + Expansion)
Foundayo was FDA-approved in 2026 for chronic weight management — the first oral, non-peptide, small-molecule GLP-1 receptor agonist. Core approval based on ATTAIN-1 (Wharton et al., NEJM 2025, PMID 40960239). ATTAIN-OSA (NCT06649045, primary completion Nov 2026) is the active expansion program for an obstructive sleep apnea indication.
How we verify this tracker
- Every NCT ID verified by direct lookup on ClinicalTrials.gov before publication. We confirm trial name, sponsor, indication, and primary completion date from the canonical record.
- Every PMID confirmed by direct PubMed lookup. Secondary sources citing the wrong PMID are corrected and flagged (e.g., retatrutide PMID 37296075 is a triboelectric sensor paper; survodutide Phase 2 is Lancet Diab & Endocrinol 2024, not NEJM).
- Manufacturer press releases are sourced to investor relations URLs with verbatim quotation marks. We do not paraphrase topline claims.
- Topline vs peer-reviewed labels are explicit. Survodutide SYNCHRONIZE-1 and pemvidutide MOMENTUM are press-release-only as of May 2026.
What is not in this tracker (verifier-rejected)
The following entries were excluded because primary-source verification found no confirmed NCT ID, publication, or manufacturer announcement:
- TRIUMPH-5 / discrete retatrutide MASH Phase 3 — no NCT confirmed as of May 2026.
- ATTAIN-MASH or ATTAIN-CVOT — no specific NCT confirmed.
- SYNCHRONIZE-MASH / LIVERAGE — no confirmed NCT for survodutide MASH Phase 3.
- DREAM-1 / DREAM-2 (petrelintide) — the correct trial name is ZUPREME, not DREAM.
- Mazdutide NEJM PMID — not yet confirmed by direct PubMed lookup as of May 2026.
Primary sources cited
- Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. PMID 37366315
- ClinicalTrials.gov NCT05929066 — TRIUMPH-1. clinicaltrials.gov →
- ClinicalTrials.gov NCT05929079 — TRIUMPH-2. clinicaltrials.gov →
- ClinicalTrials.gov NCT05931367 — TRIUMPH-4. clinicaltrials.gov →
- Jastreboff AM et al. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial. N Engl J Med. 2025;393:843–857. PMID 40549887
- ClinicalTrials.gov NCT06858839 — MARITIME-1. clinicaltrials.gov →
- Lau DCW et al. Efficacy and safety of once-weekly cagrilintide for weight management in adults with overweight and obesity. Lancet. 2021. PMID 34798060
- ClinicalTrials.gov NCT05567796 — REDEFINE-1. clinicaltrials.gov →
- le Roux CW et al. Efficacy and safety of survodutide for overweight and obesity. Lancet Diabetes Endocrinol. 2024. PMID 38330987
- Wharton S et al. Orforglipron for the Treatment of Obesity. N Engl J Med. 2025. PMID 40960239
- ClinicalTrials.gov NCT06066515 — SYNCHRONIZE-1. clinicaltrials.gov →
- ClinicalTrials.gov NCT06662539 — ZUPREME-1. clinicaltrials.gov →